-
Je něco špatně v tomto záznamu ?
Evolutionary selected Tibetan variants of HIF pathway and risk of lung cancer
L. Lanikova, NS. Reading, H. Hu, T. Tashi, T. Burjanivova, A. Shestakova, B. Siwakoti, BK. Thakur, CB. Pun, A. Sapkota, S. Abdelaziz, BJ. Feng, CD. Huff, M. Hashibe, JT. Prchal,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2010
Freely Accessible Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
- MeSH
- aklimatizace MeSH
- faktor 1 indukovatelný hypoxií - podjednotka alfa genetika metabolismus MeSH
- hypoxie genetika metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory plic genetika metabolismus MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Tibet MeSH
Tibetans existed in high altitude for ~25 thousand years and have evolutionary selected unique haplotypes assumed to be beneficial to hypoxic adaptation. EGLN1/PHD2 and EPAS1/HIF-2α, both crucial components of hypoxia sensing, are the two best-established loci contributing to high altitude adaptation. The co-adapted Tibetan-specific haplotype encoding for PHD2:p.[D4E/C127S] promotes increased HIF degradation under hypoxic conditions. The Tibetan-specific 200 kb EPAS1 haplotype introgressed from an archaic human population related to Denisovans which underwent evolutionary decay; however, the functional variant(s) responsible for high-altitude adaptation at EPAS1/HIF-2α have not yet been identified. Since HIF modulates the behavior of cancer cells, we hypothesized that these Tibetan selected genomic variants may modify cancer risk predisposition. Here, we ascertained the frequencies of EGLN1D4E/C127S and EGLN1C127S variants and ten EPAS1/HIF-2α variants in lung cancer patients and controls in Nepal, whose population consists of people with Indo-Aryan origin and Tibetan-related Mongoloid origin. We observed a significant association between the selected Tibetan EGLN1/PHD2 haplotype and lung cancer (p=0.0012 for D4E, p=0.0002 for C127S), corresponding to a two-fold increase in lung cancer risk. We also observed a two-fold or greater increased risk for two of the ten EPAS1/HIF-2α variants, although the association was not significant after correcting for multiple comparisons (p=0.12). Although these data cannot address the role of these genetic variants on lung cancer initiation or progression, we conclude that some selected Tibetan variants are strongly associated with a modified risk of lung cancer.
B P Koirala Memorial Cancer Hospital Bharatpur Chitwan Nepal
Department of Dermatology University of Utah School of Medicine Salt Lake City Utah USA
Division of Hematology University of Utah School of Medicine Salt Lake City Utah USA
University of Texas MD Anderson Cancer Center Houston Texas USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031181
- 003
- CZ-PrNML
- 005
- 20171025122905.0
- 007
- ta
- 008
- 171025s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.18632/oncotarget.14340 $2 doi
- 035 __
- $a (PubMed)28036300
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Lanikova, Lucie $u Division of Hematology, University of Utah School of Medicine, Salt Lake City, Utah, USA. Institute of Molecular Genetics, Academy of Sciences, Prague, Czech Republic.
- 245 10
- $a Evolutionary selected Tibetan variants of HIF pathway and risk of lung cancer / $c L. Lanikova, NS. Reading, H. Hu, T. Tashi, T. Burjanivova, A. Shestakova, B. Siwakoti, BK. Thakur, CB. Pun, A. Sapkota, S. Abdelaziz, BJ. Feng, CD. Huff, M. Hashibe, JT. Prchal,
- 520 9_
- $a Tibetans existed in high altitude for ~25 thousand years and have evolutionary selected unique haplotypes assumed to be beneficial to hypoxic adaptation. EGLN1/PHD2 and EPAS1/HIF-2α, both crucial components of hypoxia sensing, are the two best-established loci contributing to high altitude adaptation. The co-adapted Tibetan-specific haplotype encoding for PHD2:p.[D4E/C127S] promotes increased HIF degradation under hypoxic conditions. The Tibetan-specific 200 kb EPAS1 haplotype introgressed from an archaic human population related to Denisovans which underwent evolutionary decay; however, the functional variant(s) responsible for high-altitude adaptation at EPAS1/HIF-2α have not yet been identified. Since HIF modulates the behavior of cancer cells, we hypothesized that these Tibetan selected genomic variants may modify cancer risk predisposition. Here, we ascertained the frequencies of EGLN1D4E/C127S and EGLN1C127S variants and ten EPAS1/HIF-2α variants in lung cancer patients and controls in Nepal, whose population consists of people with Indo-Aryan origin and Tibetan-related Mongoloid origin. We observed a significant association between the selected Tibetan EGLN1/PHD2 haplotype and lung cancer (p=0.0012 for D4E, p=0.0002 for C127S), corresponding to a two-fold increase in lung cancer risk. We also observed a two-fold or greater increased risk for two of the ten EPAS1/HIF-2α variants, although the association was not significant after correcting for multiple comparisons (p=0.12). Although these data cannot address the role of these genetic variants on lung cancer initiation or progression, we conclude that some selected Tibetan variants are strongly associated with a modified risk of lung cancer.
- 650 _2
- $a aklimatizace $7 D000064
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoxie $x genetika $x metabolismus $7 D000860
- 650 _2
- $a faktor 1 indukovatelný hypoxií - podjednotka alfa $x genetika $x metabolismus $7 D051795
- 650 _2
- $a nádory plic $x genetika $x metabolismus $7 D008175
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a Tibet $7 D018609
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Reading, N Scott $u Division of Hematology, University of Utah School of Medicine, Salt Lake City, Utah, USA. Institute for Clinical and Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah, USA. Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- 700 1_
- $a Hu, Hao $u University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
- 700 1_
- $a Tashi, Tsewang $u Division of Hematology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- 700 1_
- $a Burjanivova, Tatiana $u Department of Molecular Biology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Slovak Republic.
- 700 1_
- $a Shestakova, Anna $u Division of Hematology, University of Utah School of Medicine, Salt Lake City, Utah, USA. Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- 700 1_
- $a Siwakoti, Bhola $u B.P. Koirala Memorial Cancer Hospital, Bharatpur, Chitwan, Nepal.
- 700 1_
- $a Thakur, Binay Kumar $u B.P. Koirala Memorial Cancer Hospital, Bharatpur, Chitwan, Nepal.
- 700 1_
- $a Pun, Chin Bahadur $u B.P. Koirala Memorial Cancer Hospital, Bharatpur, Chitwan, Nepal.
- 700 1_
- $a Sapkota, Amir $u Maryland Institute for Applied Environmental Health, and University of Maryland College Park School of Public Health, Maryland, USA.
- 700 1_
- $a Abdelaziz, Sarah $u Division of Public Health, Department of Family & Preventive Medicine and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA. $7 gn_A_00000307
- 700 1_
- $a Feng, Bing-Jian $u Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- 700 1_
- $a Huff, Chad D $u University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
- 700 1_
- $a Hashibe, Mia $u Division of Public Health, Department of Family & Preventive Medicine and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- 700 1_
- $a Prchal, Josef T $u Division of Hematology, University of Utah School of Medicine, Salt Lake City, Utah, USA. Department of Pathophysiology and 1st Department of Medicine, 1st Faculty of Medicine, Charles University in Prague, Czech Republic.
- 773 0_
- $w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 8, č. 7 (2017), s. 11739-11747
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28036300 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171025122947 $b ABA008
- 999 __
- $a ok $b bmc $g 1254774 $s 992208
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 8 $c 7 $d 11739-11747 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
- LZP __
- $a Pubmed-20171025
